Cheap Diabetes and Lung Medicine Deals Show Up on TrumpRx

TrumpRx, the discount program that launched in January to cut prescription costs, has just added three new drugs. Two are for type 2 diabetes—Jentadueto and its extended‑release version Jentadueto XR. The third, Striverdi Respimat, treats chronic obstructive pulmonary disease (COPD). All three come from the German company Boehringer Ingelheim. The price changes are dramatic. Where the diabetes drugs normally cost about $525 a month, TrumpRx lists them for roughly $55. The COPD inhaler has dropped from about $276 to just $35, according to the White House. Even though a generic version of Jentadueto already sells for $25 to $35 at pharmacies, the TrumpRx price remains competitive. The program is limited. Discounts apply only when patients pay cash; they cannot be combined with insurance and do not affect deductibles. Experts say TrumpRx is not a comprehensive fix for high drug prices, but rather a small tool that can help some people.So far the site lists fewer than 60 brand‑name drugs, many of which already have cheaper generic alternatives. Similar savings are available on other discount sites, and it is unclear how many people actually use TrumpRx. A recent survey found that only about one in three prescription users have heard of the program, and just 7 % have checked its prices. Among those on GLP‑1 diabetes drugs, about 16 % reported looking at TrumpRx. Despite these options, many Americans still face cost barriers. A recent poll showed that a third of adults had to cut back or skip medications in the past year to afford health care. The White House has not released usage statistics for TrumpRx since it opened, leaving its real impact uncertain.